These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1634909)

  • 1. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study.
    Rondot P; Ziegler M
    J Neurol; 1992; 239 Suppl 1():S28-34. PubMed ID: 1634909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Action of piribedil in Parkinson disease. Multicenter study].
    Ziégler M; Rondot P
    Presse Med; 1999 Sep; 28(26):1414-8. PubMed ID: 10518963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piribedil in Parkinson's syndrome: a clinical study.
    Engel J; Granerus AK; Svanborg A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):223-6. PubMed ID: 183960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
    Mentenopoulos G; Katsarou Z; Bostantjopoulou S; Logothetis J
    Clin Neuropharmacol; 1989 Feb; 12(1):23-8. PubMed ID: 2713865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.
    Montastruc JL; Ziegler M; Rascol O; Malbezin M
    Mov Disord; 1999 Mar; 14(2):336-41. PubMed ID: 10091630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
    Sweet RD; Wasterlain C; McDowell FH
    Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
    [No Abstract]   [Full Text] [Related]  

  • 15. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease: pathological mechanisms and actions of piribedil.
    Jenner P
    J Neurol; 1992; 239 Suppl 1():S2-8. PubMed ID: 1634907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study.
    Tan EK; Ratnagopal P; Han SY; Wong MC
    Acta Neurol Scand; 2003 Mar; 107(3):202-6. PubMed ID: 12614313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 19. Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience.
    Evidente VG; Esteban RP; Domingo FM; Carbajal LO; Parazo MA
    Parkinsonism Relat Disord; 2003 Dec; 10(2):117-21. PubMed ID: 14644004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.